Efficacy Disease state Safety Previous Next FACE IPF HEAD ON and modify disease progression by slowing lung function decline NINTEDANIB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-)1 01/06/2022 | Author: Boehringer IngelheimNINTEDANIB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-)1 Document ID: PC-LB-100359 Efficacy PPF in CTD-ILD: How does nintedanib fit in with background treatments for underlying CTDs? NINTEDANIB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-)1 Inbuild -On poster INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: Mortality data in INPULSIS-ON RELATED CONTENT Read more 3:37 PPF in CTD-ILD: How does… PC-AE-102132 ( May 2026 ) Watch now Opens in new tab Read more PDF Inbuild -On poster PC-LB-101062 ( February 2025 ) Download Opens in new tab Read more 2:22 INPULSIS-ON Prof. Richeldi &… PC-JO-100267 ( February 2025 ) Watch now Opens in new tab Home Respiratory Ofev Efficacy NINTEDANIB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-)1
Read more 2:22 INPULSIS-ON Prof. Richeldi &… PC-JO-100267 ( February 2025 ) Watch now Opens in new tab